肝血管病变与肝硬化的关系

宁会彬; 尚佳

doi:10.3969/j.issn.1001-5256.2018.01.005

肝血管病变与肝硬化的关系

DOI: 10.3969/j.issn.1001-5256.2018.01.005

宁会彬,
尚佳

河南省人民医院感染科

详细信息

中图分类号: R575
计量
- 文章访问数: 2506
- HTML全文浏览量: 31
- PDF下载量: 540
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

Association between liver vascular lesions and liver cirrhosis

Department of Infectious Diseases, Henan Provincial People′s Hospital, Zhengzhou 450000, China

摘要

摘要: 临床上多种原因可引起肝纤维化及肝硬化,其中肝血管病变所致肝硬化进展隐匿,临床医生认识不足,诊疗技术有限,患者预后往往较差。肝血管系统结构特殊,病变部位及范围不同其临床表现及预后也不相同。如何对不同类别肝血管病变所致肝硬化进行正确的诊断和鉴别是临床中需要关注的重点和难点。归纳了门静脉病变、肝静脉病变、肝窦病变以及肝动脉病变与肝硬化的关系,从根本上认识和掌握上述病变的临床表现、病理特点及鉴别诊断要点,对肝血管病变的正确诊断和治疗具有积极意义。
- 肝硬化 /
- 肝血管病变 /
- 诊断,鉴别
Abstract: Many factors can cause liver fibrosis and cirrhosis in clinical practice, and liver cirrhosis caused by liver vascular lesions often has insidious progression. Due to a lack of knowledge in clinicians and limited diagnostic and treatment techniques, patients often have poor prognosis. The liver vascular system has a unique structure, and patients with different locations and extents of lesion have different clinical manifestations and outcomes. Correct diagnosis and differentiation of liver cirrhosis caused by different types of liver vascular lesions is an important and difficult issue and needs careful attention in clinical practice. This article summarizes the association of portal vein lesion, hepatic vein lesion, hepatic sinusoid lesion, and hepatic artery lesion with liver cirrhosis. A deep understanding of the clinical manifestations, pathological features, and key points in differential diagnosis of these lesions helps with correct diagnosis and treatment of such disease.
- liver cirrhosis /
- liver vascular lesions /
- diagnosis, differential

HTML全文

参考文献(21)

[1]MADSEN MS, PETERSEN TH, SOMMER H.Segmental portal hypertension[J].Ann Surg, 1986, 204 (1) :72-77.

[2]SUN SZ, CHENG B.Diagnosis and differential diagnosis of hepatic vascular diseases[J].Chin J Diagn Pathol, 2014, 21 (6) :371-376. (in Chinese) 孙锁柱, 程波.肝血管性疾病的诊断与鉴别诊断[J].诊断病理学杂志, 2014, 21 (6) :371-376.

[3]PLESSIER A, RAUTOU PE, VALLA DC.Management of hepatic vascular diseases[J].J Hepatol, 2012, 56 (Suppl 1) :s25-s38.

[4]NAKANUMA Y, TSUNEYAMA K, OHBU M, et al.Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver[J].Pathol Res Pract, 2001, 197 (2) :65-76.

[5]PLESSIER A, DARWISH-MURAD S, HERNANDEZ-GUERRA M, et al.Acute portal vein thrombosis unrelated to cirrhosis:a prospective multicenter follow-up study[J].Hepatology, 2010, 51 (1) :210-218.

[6]TANAKA T, SUGAWARA Y, KOKUDO N.The current clinical aspects of idiopathic portal hypertension[J].Intractable Rare Dis Res, 2013, 2 (3) :94-97.

[7]RIGGIO O, GIOIA S, PENTASSUGLIO I, et al.Idiopathic noncirrhotic portal hypertension:current perspectives[J].Hepat Med, 2016, 8:81-88.

[8]RAFFA S, REVERTER JC, SEIJO S, et al.Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis[J].Clin Gastroenterol Hepatol, 2012, 10 (1) :72-78.

[9]OKUDAIRA M, OHBU M, OKUDA K.Idiopathic portal hypertension and its pathology[J].Semin Liver Dis, 2002, 22 (1) :59-72.

[10]European Association for the Study of the Liver.EASL clinical practice guidelines:vascular diseases of the liver[J].J Hepatol, 2016, 64 (1) :179-202.

[11]SARIN SK, KAPOOR D.Non-cirrhotic portal fibrosis:current concepts and management[J].J Gastroenteral Hepatol, 2002, 17 (5) :526-534.

[12]DARWISH MURAD S, PLESSIER A, HERNANDEZ-GUERRA M, et al.Etiology, management, and outcome of the Budd-Chiari syndrome[J].Ann Intern Med, 2009, 151 (3) :167-175.

[13]SMALBERG JH, ARENDS LR, VALLA DC, et al.Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis:a meta-analysis[J].Blood, 2012, 120 (25) :4921-4928.

[14]PLOMPEN EP, VALK PJ, CHU I, et al.Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis[J].Haematologica, 2015, 100 (6) :e226-e228.

[15]BAYRAKTAR Y, BALKANCI F, BAYRAKTAR M, et al.BuddChiari syndrome:a common complication of Behcet's disease[J].Am J Gastroenterol, 1997, 92 (5) :858-862.

[16]RUBBIA-BRANDT L.Sinusoidal obstruction syndrome[J].Clin Liver Dis, 2010, 14 (4) :651-668.

[17]COPPELL JA, RICHARDSON PG, SOIFFER R, et al.Hepatic veno-occlusive disease following stem cell transplantation:incidence, clinical course, and outcome[J].Biol Blood Marrow Transplant, 2010, 16 (2) :157-168.

[18]ANGLIVIEL B, BENOIST S, PENNA C, et al.Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases[J].Ann Surg Oncol, 2009, 16 (5) :1247-1253.

[19]RICHARDSON PG, SMITH AR, TRIPLETT BM, et al.Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome:interim results from a treatment IND study[J].Biol Blood Marrow Transplant, 2017, 23 (6) :997-1004.

[20]BROUQUET A, BENOIST S, JULIE C, et al.Risk factors for chemotherapy-associated liver injuries:a multivariate analysis of a group of 146 patients with colorectal metastases[J].Surgery, 2009, 145 (4) :362-371.

[21]STANGE BJ, GLANEMANN M, NUESSLER NC, et al.Hepatic artery thrombosis after adult liver transplantation[J].Liver Transpl, 2003, 9 (6) :612-620.

施引文献

资源附件(0)

访问统计